Biweekly vinorelbine and gemcitabine: A phase I dose-finding study in patients with advanced solid tumors

Annals of Oncology

Volumn 14, Issue 5, 2003, Pages 783-787

  Castellano, Danica ^a   Hitt, R ^a   Ciruelos, E ^a   Cortes Funes H ^a   Colomer, R ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Advanced solid tumors; Biweekly schedule; Gemcitabine; Metastatic carcinoma; Phase I trial; Vinorelbine

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; GEMCITABINE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; SKIN MANIFESTATION; SOLID TUMOR; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; VINBLASTINE;

EID: 0038781775     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg196     Document Type: Article

References (27)

1. Ashizawa T, Miyoshi K, Asada M et al. Anti-tumour activity of navelbine, a new vinca-alkaloid analog. Gan To Kagaku Ryoho 1993; 20: 59-66.
2. Besenval M, Delgado M, Demarez JP, Krikorian A. Safety and tolerance of Navelbine in phase I-II clinical trials. Semin Oncol 1989; 16 (Suppl 4): 37-40.
3. Abbruzzese JL, Grunewald R, Weeks EA et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-498.
4. Tonato M, Mosconi A, Martin C. Safety profile of gemcitabine. Anticancer Drugs 1995; 6 (Suppl 6): 27-32.
5. Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23 (Suppl 10): 32-35.
6. Plunkett W, Mergenthaler HG, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995; 6 (Suppl 6): 7-13.
7. Colomer R, Llombart A, Lluch A et al. Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. Semin Oncol 2000; 27 (1 Suppl 2): 20-24.
8. Isla D, Rosell R, Sanchez JJ et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2001; 19: 1071-1077.
9. Sanchez Rovira P, Jaen A, Gonzalez E et al. Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial. Oncology (Huntingt) 2001; 15 (2 Suppl 3): 44-47.
10. Arbuck SG, Ivy SP, Setser A et al. The revised common toxicity criteria: version 2.0. CTEP website [on-line]. http://ctep.info.nih.gov (10 February 2003, date last accessed).
11. Gregory RK, Smith IE. Vinorelbine a clinical review. Br J Cancer 2000; 82: 1907-1913.
12. Johnson SA, Harper P, Hortobagyi GN et al. Vinorelbine: an overview. Cancer Treat Rev 1996; 22: 127-142.
13. Lorusso V, Carpagnano F, Frasci G et al. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Clin Oncol 2000; 18: 405-411.
14. Frasci G, Lorusso V, Panza N et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18: 2529-2536.
15. Caristi N, Maisano R, Spadaro P et al. Gemcitabine and vinorelbine in combination in patients older than 70 years or unresponsive to a cisplatin chemotherapy in advanced bladder cancer. Proc Am Soc Clin Oncol 2000; 19: 362a (Abstr 1429).
16. Valenza R, Leonardi V, Gebbia V et al. Gemcitabine and vinorelbine in pretreated advanced breast cancer: A pilot study. Ann Oncol 2000; 11: 495-496.
17. Tagliabue P, Mariani G, Brambilla C et al. Dose-finding study of gemcitabine (G) plus vinorelbine (V) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1999; 18: 112a (Abstr 423).
18. Hirsch V, Ayoub J, Cormier Y et al. Phase II multi-center trial with gemcitabine and vinorelbine in patients with advanced (Stage IIIB + IV) non-small-cell lung cancer. Proc Am Soc Clin Oncol 1999; 18: 508a (Abstr 1961).
19. Gian V, Hainsworth JD, Burris HA et al. Combination of gemcitabine and vinorelbine in the second-line treatment of non-small-cell lung cancer (NSCLC): a phase II study of the Minnie Pearl Cancer Research Network. Proc Am Soc Clin Oncol 1999; 18: 505a (Abstr 1949).
20. Greenhawt M, Jahanzeb M, Koletsky A et al. A phase I trial of vinorelbine and gemcitabine in relatively elderly patients with refractory solid tumors. Proc Am Soc Clin Oncol 1999; 18: 233a (Abstr 897a).
21. Herbst RS, Khuri FR, Jung M et al. Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small-cell lung cancer. Proc Am Soc Clin Oncol 1999; 18: 462a (Abstr 1782).
22. Pirker R, Krajnik G, Mohn-Staudner A et al. Vinorelbine/gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Proc Am Soc Clin Oncol 1999; 18: 479a (Abstr 1849).
23. Castellano D, Hitt R, Cortes-Funes H et al. Radiation recall reaction induced by gemcitabine. J Clin Oncol 2000; 18: 695-696.
24. Abbruzzese H, Gravel D, Tarassoff P et al. Pharmacologically directed strategy for dose intensification of gemcitabine: a phase I trial. Proc Am Assoc Cancer Res 1993; 34: (Abstr A2233).
25. Fosella F, Abruzzese J, Pang A et al. Phase I studies of gemcitabine. Eur J Cancer 1993; 29 (Suppl 6): S119 (Abstr 645).
26. Ulrich-Pur H, Kornek GV, Raderer M et al. A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer 2000; 8: 2505-2511.
27. Isokangas OP, Knuuttila A, Halme M et al. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer. Ann Oncol 1999; 10: 1059-1063.